Last reviewed · How we verify
Dl-Alpha-Methylbenzyl Linoleamide (MELINAMIDE)
Dl-Alpha-Methylbenzyl Linoleamide (generic name: MELINAMIDE) is a drug. It is currently in Phase 2 development.
MELINAMIDE is a small molecule that works by interacting with a specific target in the body to produce a therapeutic effect.
Dl-Alpha-Methylbenzyl Linoleamide, also known as AC-223, ARTES, MELINAMIDA, or MELINAMIDE, is a small molecule. Its exact mechanism and indications are not specified in the provided information.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MELINAMIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine MELINAMIDE as a key that fits into a lock in the body. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This process is complex and involves many different molecules and cellular pathways.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dl-Alpha-Methylbenzyl Linoleamide CI brief — competitive landscape report
- Dl-Alpha-Methylbenzyl Linoleamide updates RSS · CI watch RSS
Frequently asked questions about Dl-Alpha-Methylbenzyl Linoleamide
What is Dl-Alpha-Methylbenzyl Linoleamide?
How does Dl-Alpha-Methylbenzyl Linoleamide work?
What is the generic name of Dl-Alpha-Methylbenzyl Linoleamide?
What development phase is Dl-Alpha-Methylbenzyl Linoleamide in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing